Thermo Fisher Scientific Inc.
TMOHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframeThermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. At a $197.88B market cap, Thermo Fisher Scientific Inc. ranks as a large-cap company within healthcare. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Market Cap
$197.88B
Beta
0.87
P/E (TTM)
29.85
P/E (Fwd)
19.54
EPS (TTM)
$17.84
EPS (Fwd)
$27.26
ROE
13.5%
ROA
5.0%
Cash
$3.26B
Total Debt
$43.16B
Free CF
$5.52B
52W Change
28.4%
Annual Financials
Cash vs Debt
The company holds $3.26B in cash, though total debt stands at $43.16B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $5.52B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 13.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 5.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $39.21B to $44.56B.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Thermo Fisher Scientific Inc. and its sector.